Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Allovate Therapeutics, LLC
WARNING LETTER
•Allovate Therapeutics, LLC•September 1, 2025

Allovate Therapeutics, LLC – FDA Warning Letter, Sep 1, 2025

Record Details

On September 30, 2025, the FDA issued a Warning Letter to Allovate Therapeutics, LLC, citing significant violations related to their product, Allerdent, an allergenic toothpaste. The FDA"s Center for Biologics Evaluation and Research (CBER) conducted a review of the company"s marketing materials, including a brochure last visited in September 2025, which promotes Allerdent for allergy immunotherapy through daily tooth brushing.

The core issues identified are that Allerdent is marketed as an unapproved new drug, violating section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), and as an unlicensed biological product, violating section 351(a)(1) of the Public Health Service Act (PHS Act). The FDA determined that, by its intended use to diagnose, treat, or prevent disease, Allerdent falls under the definitions of both a drug and a biological product. Consequently, it requires either an approved Biologics License Application (BLA) or a New Drug Application, neither of which Allovate Therapeutics possesses.

Allovate Therapeutics is required to submit a written response within fifteen working days of receiving the letter. This response must outline the specific corrective actions taken or planned to address these violations and prevent their recurrence, accompanied by supporting documentation. If the company cannot meet this timeframe or disputes the findings, an explanation or justification is expected. Failure to adequately address these matters may result in further regulatory enforcement, such as product seizure or injunction.

Company
Allovate Therapeutics, LLC
Inspection date
September 1, 2025
Product type
Drugs
Office
Center for Biologics Evaluation and Research
Person
  • Melissa J. Mendoza (Director)
View Company Profile

ID · d1a2fed7-ad57-4cdb-bd62-95146f3ad98d

Violation Codes8
FD&C Act 505(a)21.U.S.C. 355(a)FD&C Act 50521 U.S.C. 355FD&C Act 301(d)21 U.S.C. 331(d)FD&C Act 201(g)(1)21 U.S.C. 321(g)(1)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Allovate Therapeutics, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.